


Emerging Challenges in Primary Care 2018 17th Annual Regional and Online CME Conference Series

The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes


Participation and Demographics



Attendee Patient Care Focus: 93%


2018 Meeting/Simulcast	Date	Attendees
Miami, FL	4/28/18	179
Baltimore, MD	5/5/18	218
Baltimore, MD Simulcast	5/5/18	372
St. Louis, MO	5/12/18	129
Atlanta, GA	6/2/18	233
Atlanta, GA Simulcast	6/2/18	296
Raleigh, NC	6/16/18	168
Virtual Symposium	6/23/18	655
TOTAL		2250

Learning Gains Across Objectives



- 37% Improvement: Describe newer concepts in the pathophysiology of asthma and type 2 inflammation and the implications of biologic therapies in the era of precision medicine.
- 23% Improvement: Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral.
- 19% Improvement: Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment.
- 13% Improvement: Discuss the paradigms of multidisciplinary care in asthma with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma.


Learning Domain Analysis




- The increase in Knowledge from Pre- to Post-Test was exclusively driven by one of the two questions related to examples of type-2 asthma; in contrast, the average score on the question about Anti-IL-5 agents showed a modest decrease.
- Learners substantially (74%) increased their reported Confidence in their ability to differentiate phenotypes of asthma. The Post-Test average rating, however, remained low.
- There was a substantial (32%) increase in their reported intent to treat comorbidities to improve asthma control.

4-Week Retention Analysis

LEARNING RETENTION: Statistically significant net gains were measured from Pre-Test to the Post Curriculum Assessment (PCA) in all learning domains. The greatest net increases were observed in the Knowledge and Confidence domains.





N= 533 +23.34%* +58.69%* 4.29 4.00 (0.83)(0.94)3.30 3.24 3.02 (0.80)(1.12)(0.88)1.90 (0.94)Confidence Practice Pre-Test Post-Test PCA

Some score slippage was observed in all domains from Post-Test to PCA. However, this slippage was modest compared to the net gains from Pre-Test to the PCA.

AstraZeneca Grant ID: 38096395

5.00

4.00

3.00

2.00

1.00

